01 — The bite
A bite floods the blood with venom.
In seconds, a snakebite injects a cocktail of phospholipase‑A2 and neurotoxins straight into the bloodstream — spreading through the vessel far faster than a victim can reach help.
VenoShield neutralises venom on contact — swallowed, not injected. No cold chain. No species guesswork.
Snakebite is the world's largest neglected tropical disease — and India carries the heaviest burden on Earth. The only treatment, antivenom, was designed over 100 years ago.
Venom varies between species, between regions, even within a single snake's lifetime. Antivenom made from animal proteins can trigger life-threatening anaphylaxis — so doctors often wait for symptoms before treating. In rural fields, hours from care, that wait is fatal.
Horse antibodies, region-specific, refrigerated, IV-administered — and frequently ineffective against the very snake that bit you.
A small-molecule oral tablet that blocks the toxins common across venoms — carried by the people most at risk, used the moment a bite happens.
In seconds, a snakebite injects a cocktail of phospholipase‑A2 and neurotoxins straight into the bloodstream — spreading through the vessel far faster than a victim can reach help.
Venom enzymes shred cell membranes and jam nerve signals — driving paralysis, internal bleeding and tissue death long before antivenom can ever be administered.
Swallowed the instant a bite happens, VenoShield's small molecules reach the bloodstream and seek out the venom's active toxins — no diagnosis, no cold chain, no needle.
Each molecule binds and inhibits a toxin, switching it off. Paralysis is delayed, tissue is spared — and the body wins back the hours it needs to survive the journey to care.
Beneath the skin, bundles of muscle fibres sit cradled in the extracellular matrix — the collagen scaffold that holds living, working tissue together.
Fangs puncture the muscle and inject venom straight into the matrix. Myotoxins flood the spaces between the fibres, swarming them from every side.
Toxins tear open the fibre membranes. Striations break down and the tissue begins to necrose — the local muscle death that conventional antivenom reaches far too late to stop.
VenoShield's small molecules reach the bite site and lock onto the toxins where they strike — binding and inhibiting the venom before it can destroy more tissue.
With the venom neutralised, VenoShield also limits fibrotic signalling — curbing the scar-tissue response so fibres regenerate instead of hardening. The matrix rebuilds, repair sets in, and healthy muscle function is preserved.
In preclinical testing, a single oral dose delivered broad, cross-species protection — the foundation of a truly universal antidote.
Our development path — from foundational research to a tiered global rollout, structured for emergency authorisation in the world's highest-burden geographies first.
Twenty years of venom pharmacology and biochemistry, distilled into a patented combination of repurposed small molecules — with confirmed freedom to operate.
Foundation phase completeValidated across 70+ venoms globally — vipers, cobras, kraits and asps. Delay-to-death in 100% of animals tested, and protection against 95% of bites from a single oral dose.
Preclinical validation completeA clinical trial plan published and cleared. Phase I safety studies in healthy volunteers are in preparation, followed by Phase II in snakebite patients in a high-burden geography.
Phase I ~Q2 2026 · Phase II ~Q3 2026A multi-region plan: early access in the highest-burden countries, scalable procurement across global-health markets, and structured approval in developed healthcare systems.
First approvals targeted October 2026Because it's oral and heat-stable, VenoShield can be stocked in clinics, pharmacies and field kits — not just hospitals with a cold chain. India-first launch through a pharma partner.
First launch targeted late 2026A tiered rollout from India into South Asia — Bangladesh, Pakistan and Sri Lanka — then Latin America, Africa, Southeast Asia and developed markets.
Phased rollout from late 2026 onwardsBecause it's heat-stable and oral, VenoShield can live in clinics, pharmacies and field kits — not just hospitals with cold chain. That changes who gets to be saved.
Launch market and clinical home — the world's highest snakebite burden.
Bangladesh, Pakistan and Sri Lanka — shared snakes, shared need.
Sub-Saharan Africa, Southeast Asia and Latin America via global health markets.
Structured approval in high-income healthcare systems and travel medicine.
Partner, fund or pilot VenoShield — and help put a universal antidote in the pocket of every person at risk.